CTLA-4 is a validated immune checkpoint. The challenge in 2026 is no longer validation — it’s designing differentiated anti-CTLA-4 antibodies with a clear edge on efficacy, tolerance and IP. MAbSilico engineers next-generation CTLA-4 candidates from 1,147 annotated antibodies, 450+ affinity measurements and 22 INNs.
In 2026, how do you design anti-CTLA-4 antibodies that stand out on efficacy, tolerance and IP? Monoclonal, bispecific or innovative formats — which one positions a candidate against first-generation drugs and the rising wave of next-gen molecules?
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is an inhibitory receptor expressed on activated T cells and constitutively on regulatory T cells (Tregs). It competes with CD28 for binding CD80 and CD86, acting as a key negative regulator of T-cell activation.
Dual inhibition mechanism
Structure. Type I transmembrane glycoprotein · 41–43 kDa homodimer · IgV extracellular domain recognizing CD80/CD86 · C-terminal domain recruiting phosphatases.
Blocking CTLA-4 restores T-cell activation in lymph nodes and reduces Treg suppression in the tumor microenvironment. As the first immune checkpoint to be therapeutically validated (ipilimumab, 2011), CTLA-4 blockade remains a cornerstone of combination immunotherapy strategies.
Ipilimumab (Yervoy, BMS) received FDA approval in 2011 for unresectable or metastatic melanoma, expanding to multiple solid tumors in combination with nivolumab. Tremelimumab (Imjudo, AstraZeneca) received approval in 2022 for hepatocellular carcinoma in the STRIDE regimen.
First-generation CTLA-4 antibodies carry dose-limiting toxicity from systemic immune activation. The key engineering challenges are: (1) improved Fc-mediated Treg depletion at the tumor site, (2) selective activity to reduce irAEs, and (3) differentiated epitope engagement beyond the ipilimumab footprint.
| Antibody | Isotype | Mechanism | Indication |
|---|---|---|---|
| Ipilimumab | Human IgG1 | CTLA-4/B7 blockade · Treg depletion via ADCC/ADCP | Melanoma + anti-PD-1 |
| Tremelimumab | Human IgG2 | Lower Fc effector function | HCC (STRIDE) |
MAbSilico’s computational platform processes the entire annotated CTLA-4 antibody landscape — 1,147 antibodies, 450+ affinity measurements, 22 INNs — to identify differentiated binding modes, model Fc effector profiles and generate optimized candidate sequences ready for CRO transfer in 21 days.
Discuss your anti-CTLA-4 program with our team. Feasibility note within 48h.
Discuss a projectThe deepest annotated anti-CTLA-4 antibody dataset, engineered for computational design.
How clients engage MabSilico for their anti-CTLA-4 programs.
Design a differentiated IgG1 CTLA-4 antibody with enhanced Treg depletion and improved tolerability vs ipilimumab.
Improve affinity and developability of an existing anti-CTLA-4 scaffold with multiparameter in silico optimization.
Engineer a dual checkpoint inhibitor combining CTLA-4 and PD-1 blockade in a single molecule.
Map the CTLA-4 antibody IP landscape and identify freedom-to-operate windows for your novel candidate.
Get a feasibility note on your anti-CTLA-4 project within 48h. Phase-I-ready candidates in 21 days.
CTLA-4 is a validated immune checkpoint. The challenge in 2026 is no longer validation — it’s designing differentiated anti-CTLA-4 antibodies with a clear edge on efficacy, tolerance and IP. MAbSilico engineers next-generation CTLA-4 candidates from 1,147 annotated antibodies, 450+ affinity measurements and 22 INNs.
In 2026, how do you design anti-CTLA-4 antibodies that stand out on efficacy, tolerance and IP? Monoclonal, bispecific or innovative formats — which one positions a candidate against first-generation drugs and the rising wave of next-gen molecules?
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is an inhibitory receptor expressed on activated T cells and constitutively on regulatory T cells (Tregs). It competes with CD28 for binding CD80 and CD86, acting as a key negative regulator of T-cell activation.
Blocking CTLA-4 restores T-cell activation in lymph nodes and reduces Treg suppression in the tumor microenvironment. As the first immune checkpoint to be therapeutically validated (ipilimumab, 2011), CTLA-4 blockade remains a cornerstone of combination immunotherapy strategies.
Ipilimumab (Yervoy, BMS) received FDA approval in 2011 for unresectable or metastatic melanoma, expanding to multiple solid tumors in combination with nivolumab. Tremelimumab (Imjudo, AstraZeneca) received approval in 2022 for hepatocellular carcinoma in the STRIDE regimen.
First-generation CTLA-4 antibodies carry dose-limiting toxicity from systemic immune activation. The key engineering challenges are: (1) improved Fc-mediated Treg depletion at the tumor site, (2) selective activity to reduce irAEs, and (3) differentiated epitope engagement beyond the ipilimumab footprint.
| Antibody | Isotype | Mechanism | Indication |
|---|---|---|---|
| Ipilimumab | Human IgG1 | CTLA-4/B7 blockade · Treg depletion via ADCC/ADCP | Melanoma + anti-PD-1 |
| Tremelimumab | Human IgG2 | Lower Fc effector function | HCC (STRIDE) |
MAbSilico’s computational platform processes the entire annotated CTLA-4 antibody landscape — 1,147 antibodies, 450+ affinity measurements, 22 INNs — to identify differentiated binding modes, model Fc effector profiles and generate optimized candidate sequences ready for CRO transfer in 21 days.
Discuss your anti-CTLA-4 program with our team. Feasibility note within 48h.
Discuss a projectThe deepest annotated anti-CTLA-4 antibody dataset, engineered for computational design.
Our in silico workflow applied to CTLA-4, from epitope strategy to ready-to-clone sequences.
How clients engage MAbSilico for their anti-CTLA-4 programs.
Get a feasibility note on your anti-CTLA-4 project within 48h. Phase-I-ready candidates in 21 days.
Ipilimumab's approvals rest on a landmark series of randomized trials that established immune checkpoint blockade as a curative-intent strategy in melanoma and beyond.
The clinical success of CTLA-4 blockade is limited by dose-limiting toxicities. Next-generation antibodies use structure-guided engineering to dissociate anti-tumor efficacy from systemic irAEs.
At tumor pH (6.0–6.5), histidine residues in the antibody CDR loops become protonated, stabilizing a high-affinity conformation that tightly engages CTLA-4 on intratumoral T cells and Tregs. At systemic pH (7.4), the same histidines deprotonate, reducing affinity ~100-1000× and sparing peripheral CTLA-4+ cells. This mechanism—pioneered in gotistobart—produces tumor-selective checkpoint blockade with dramatically lower irAE rates in early-phase data.